Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28

Mythily Srinivasan, Ingrid E. Gienapp, Scott S. Stuckman, Connie J. Rogers, Scott D. Jewell, Pravin T P Kaumaya, Caroline C. Whitacre

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The B7:CD28/CTLA-4 costimulatory pathway plays a critical role in regulating the immune response and thus provides an ideal target for therapeutic manipulation of autoimmune disease. Previous studies have shown that blockade of CD28 signaling by mAbs can both prevent and exacerbate experimental autoimmune encephalomyelitis (EAE). In this study, we have designed two CD28 peptide mimics that selectively block B7:CD28 interactions. By surface plasmon resonance, both the end group-blocked CD28 peptide (EL-CD28) and its retro-inverso isomer (RI-CD28) compete effectively with the extracellular domain of CD28 for binding to B7-1. Both the CD28 peptide mimics inhibited expansion of encephalitogenic T cells in vitro. A single administration of EL-CD28 or RI-CD28 peptide significantly reduced disease severity in EAE. Importantly, we show that either CD28 peptide mimic administered during acute disease dramatically improved clinical signs of EAE, suppressing ongoing disease. The ratio of CD80: CD86 expression was significantly lower on CD4+ and F4/80+ spleen cells in CD28 peptide-treated mice. Peripheral deletion of Ag-specific CD4+ T cells occurs following in vivo blockade of CD28 with synthetic CD28 peptides.

Original languageEnglish (US)
Pages (from-to)2180-2188
Number of pages9
JournalJournal of Immunology
Volume169
Issue number4
StatePublished - Aug 15 2002
Externally publishedYes

Fingerprint

Autoimmune Experimental Encephalomyelitis
Peptides
T-Lymphocytes
Surface Plasmon Resonance
Acute Disease
Autoimmune Diseases
Spleen

ASJC Scopus subject areas

  • Immunology

Cite this

Srinivasan, M., Gienapp, I. E., Stuckman, S. S., Rogers, C. J., Jewell, S. D., Kaumaya, P. T. P., & Whitacre, C. C. (2002). Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. Journal of Immunology, 169(4), 2180-2188.

Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. / Srinivasan, Mythily; Gienapp, Ingrid E.; Stuckman, Scott S.; Rogers, Connie J.; Jewell, Scott D.; Kaumaya, Pravin T P; Whitacre, Caroline C.

In: Journal of Immunology, Vol. 169, No. 4, 15.08.2002, p. 2180-2188.

Research output: Contribution to journalArticle

Srinivasan, M, Gienapp, IE, Stuckman, SS, Rogers, CJ, Jewell, SD, Kaumaya, PTP & Whitacre, CC 2002, 'Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28', Journal of Immunology, vol. 169, no. 4, pp. 2180-2188.
Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PTP et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. Journal of Immunology. 2002 Aug 15;169(4):2180-2188.
Srinivasan, Mythily ; Gienapp, Ingrid E. ; Stuckman, Scott S. ; Rogers, Connie J. ; Jewell, Scott D. ; Kaumaya, Pravin T P ; Whitacre, Caroline C. / Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. In: Journal of Immunology. 2002 ; Vol. 169, No. 4. pp. 2180-2188.
@article{b76a7e19f57d48c38372a977aef00325,
title = "Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28",
abstract = "The B7:CD28/CTLA-4 costimulatory pathway plays a critical role in regulating the immune response and thus provides an ideal target for therapeutic manipulation of autoimmune disease. Previous studies have shown that blockade of CD28 signaling by mAbs can both prevent and exacerbate experimental autoimmune encephalomyelitis (EAE). In this study, we have designed two CD28 peptide mimics that selectively block B7:CD28 interactions. By surface plasmon resonance, both the end group-blocked CD28 peptide (EL-CD28) and its retro-inverso isomer (RI-CD28) compete effectively with the extracellular domain of CD28 for binding to B7-1. Both the CD28 peptide mimics inhibited expansion of encephalitogenic T cells in vitro. A single administration of EL-CD28 or RI-CD28 peptide significantly reduced disease severity in EAE. Importantly, we show that either CD28 peptide mimic administered during acute disease dramatically improved clinical signs of EAE, suppressing ongoing disease. The ratio of CD80: CD86 expression was significantly lower on CD4+ and F4/80+ spleen cells in CD28 peptide-treated mice. Peripheral deletion of Ag-specific CD4+ T cells occurs following in vivo blockade of CD28 with synthetic CD28 peptides.",
author = "Mythily Srinivasan and Gienapp, {Ingrid E.} and Stuckman, {Scott S.} and Rogers, {Connie J.} and Jewell, {Scott D.} and Kaumaya, {Pravin T P} and Whitacre, {Caroline C.}",
year = "2002",
month = "8",
day = "15",
language = "English (US)",
volume = "169",
pages = "2180--2188",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28

AU - Srinivasan, Mythily

AU - Gienapp, Ingrid E.

AU - Stuckman, Scott S.

AU - Rogers, Connie J.

AU - Jewell, Scott D.

AU - Kaumaya, Pravin T P

AU - Whitacre, Caroline C.

PY - 2002/8/15

Y1 - 2002/8/15

N2 - The B7:CD28/CTLA-4 costimulatory pathway plays a critical role in regulating the immune response and thus provides an ideal target for therapeutic manipulation of autoimmune disease. Previous studies have shown that blockade of CD28 signaling by mAbs can both prevent and exacerbate experimental autoimmune encephalomyelitis (EAE). In this study, we have designed two CD28 peptide mimics that selectively block B7:CD28 interactions. By surface plasmon resonance, both the end group-blocked CD28 peptide (EL-CD28) and its retro-inverso isomer (RI-CD28) compete effectively with the extracellular domain of CD28 for binding to B7-1. Both the CD28 peptide mimics inhibited expansion of encephalitogenic T cells in vitro. A single administration of EL-CD28 or RI-CD28 peptide significantly reduced disease severity in EAE. Importantly, we show that either CD28 peptide mimic administered during acute disease dramatically improved clinical signs of EAE, suppressing ongoing disease. The ratio of CD80: CD86 expression was significantly lower on CD4+ and F4/80+ spleen cells in CD28 peptide-treated mice. Peripheral deletion of Ag-specific CD4+ T cells occurs following in vivo blockade of CD28 with synthetic CD28 peptides.

AB - The B7:CD28/CTLA-4 costimulatory pathway plays a critical role in regulating the immune response and thus provides an ideal target for therapeutic manipulation of autoimmune disease. Previous studies have shown that blockade of CD28 signaling by mAbs can both prevent and exacerbate experimental autoimmune encephalomyelitis (EAE). In this study, we have designed two CD28 peptide mimics that selectively block B7:CD28 interactions. By surface plasmon resonance, both the end group-blocked CD28 peptide (EL-CD28) and its retro-inverso isomer (RI-CD28) compete effectively with the extracellular domain of CD28 for binding to B7-1. Both the CD28 peptide mimics inhibited expansion of encephalitogenic T cells in vitro. A single administration of EL-CD28 or RI-CD28 peptide significantly reduced disease severity in EAE. Importantly, we show that either CD28 peptide mimic administered during acute disease dramatically improved clinical signs of EAE, suppressing ongoing disease. The ratio of CD80: CD86 expression was significantly lower on CD4+ and F4/80+ spleen cells in CD28 peptide-treated mice. Peripheral deletion of Ag-specific CD4+ T cells occurs following in vivo blockade of CD28 with synthetic CD28 peptides.

UR - http://www.scopus.com/inward/record.url?scp=0037103157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037103157&partnerID=8YFLogxK

M3 - Article

C2 - 12165548

AN - SCOPUS:0037103157

VL - 169

SP - 2180

EP - 2188

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -